1.0 LPBI – 2012-2020 VISTA | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

1.0 LPBI – 2012-2020 VISTA

2020 VISTA is the Website for LPBI Group’s Ten Health Care Contents Asset Classes prospected for technology ownership transfer and monetization

6/3/2022

We Celebrate TEN Years of Excellence, LPBI Group: 4/2012 – 4/2022

https://pharmaceuticalintelligence.com/2022/04/25/we-celebrate-ten-years-of-excellence-lpbi-group-4-2012-4-2022/

2022 Update from LPBI Group | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

https://pharmaceuticalintelligence.com/2022/02/21/update-from-lpbi-group/

1.0 LPBI IP Asset Class I: Journal Articles by Top Authors

Equity Sharing Calculation: A Scoring System for Author’s (a) Total Articles (single author) and (b) multiple authors)(c) Total Articles Views and (d) Author’s Proportion of own articles views in the Top 14 Journal articles by Views (e) External Citations

Curators: Aviva Lev-Ari, PhD, RN and Stephen J. Williams, PhD

https://pharmaceuticalintelligence.com/2022/04/11/equity-sharing-calculation-a-scoring-system-for-authors-a-total-articles-single-author-and-multiple-authorsb-total-articles-views-and-c-authors-proportion-of-own-articles-views-in/

LinkedIn 1st degree connections by Biotech Company Name and by Connections positions

Analytics for e-Reputation based on LinkedIn 1st Degree Connections, +7,500 of LPBI Group’s Founder, 2012-2022: An Intangible Asset – Connections’ Position Seniority & Biotech / Pharma Focus

Author: Aviva Lev-Ari, PhD, RN, Founder of 1.0 LPBI, 2012-2020 & 2.0 LPBI, 2021-2025

and

Data Scientist, Research Assistant III: Tianzuo George Li

https://pharmaceuticalintelligence.com/2022/04/04/analytics-for-e-reputation-based-on-linkedin-1st-degree-connections-7500-of-lpbi-groups-founder-2012-2022-an-intangible-asset-connections-position-seniority-biotech-pharma-focus/

8/20/2021

2.0 LPBI is a Very Unique Organization

Portfolio of IP Assets: 2012-2025

https://pharmaceuticalintelligence.com/portfolio-of-ip-assets/

Pipeline Products, 2021-2025 beyond 1.0 Ten IP Asset Classes:

2.0 LPBI comprise of the following four IP Asset Classes: XI, XII, XIII, XIV

IP Asset Class XI (Queries yielding results on the Fly) – ending up in Blockchain storage available for monetization as a new product

New Digital Products as a result of Discovery 💡 of new digital products derived from and created for the new queries by users to be generated on the fly not in existence in the knowledge graph database

IP Asset Class XIV (Mission #1) – 2.0 LPBI all Products of NLP, yields for Mission #1: Generated NLP Results to be hosted on the blockchain, new to be generated by the interface of the blockchain and ML, NLP and value added creation for IP Asset Class XI – synergy between existing and new discovery

We completed Medical Text analysis with NLP for Cancer Volume 1 – will be published as New Genre Book in 2022
We completed Medical Text analysis with NLP for Genomics Volume 2 – will be published as New Genre Book in 2022

In addition, all new Digital Products of Mission #3 and Mission #4 will be stored on the Blockchain IT Infrastructure (Mission #2)

IP Asset Class XIV (Mission #2) – Blockchain schema: Knowledge graphs and edges mapping the Ontology

All digital products of Mission #2: Content Monetization on a Blockchain IT Platform, i.e., interface to NLP

IP Asset Class XII (Mission #3) – ending up in Blockchain storage available for monetization transactions as new products

All digital products of Mission #3, below: New Genre of Scientific Books N =18, see book architecture, below,

IP Asset Class XIII (Mission #4) – ending up in Blockchain storage available for monetization transactions as new products

All digital products of Mission #4, below: New therapeutics molecules generated for 12 Galectins by Synthetic Biology software

2/1/2021

Milestone achieved today:

February 1, 2021 – We Celebrate 1,924,400 e-Readers, 6,000 Scientific Journal Articles, 7,525 Scientific Comments, A Journal Ontology of 728 Medical

https://pharmaceuticalintelligence.com/2021/02/01/february-1-2021-we-celebrate-1924400-e-readers-6000-scientific-journal-articles-7525-scientific-comments-a-journal-ontology-of-728-medical-life-sciences-research-categories-10440-tag/

Thought on the transition

One Possible Strategy for an Acquisition is via a SPAC

Follow the links

9/25/2020

1.0 & 2.0 LPBI Group’s Team

8/19/2020

An UPDATE Shared with ALL

We launched on 3/14/2020 the Coronavirus PORTAL https://pharmaceuticalintelligence.com/coronavirus-portal/ which covers 8 topics:

That effort took 2 months of most intensive work on my part.

STATEMENT

The economic impact of of the Pandemic DOES HAVE A NEGATIVE EFFECT ON THE M&A MARKET
In the INTERIM awaiting for more favorable conditions on the market
we invested in INTERNAL development of IP

We launched FOUR additional PORTALS:

Artificial Intelligence in Genomics & Cancer

https://pharmaceuticalintelligence.com/ai-in-genomics-cancer/

2020 Summer Internship Portal

https://pharmaceuticalintelligence.com/2020-summer-internship/

Knowledge PORTALS System (KPS) @LPBI

https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/

2021 Medical Text Analysis (NLP)

https://pharmaceuticalintelligence.com/2021-medical-text-analysis-nlp/

As an ADJUSTMENT for submitting the documentation to the Investment Banker in 10/2020 vs the original plan 4/2020, we are working on
The Plan for 2021 – 2025. It involves six new strategies: TNS #1,2,3,4,5,6

TNS #1: TEXT Analysis on our CONTENTS: NLP, ML, AI – INSIGHTS MEAN VALUE and Up-selling content = NEW WARES to be brought to the market

Phase 1: Natural Language Processing(NLP) – 24 months FREE Microsoft AZURE for Health

Phase 2: Piloting the Proof of Concept on 4 of LPBI BioMed 16 volumes:

Cancer, Volume 1 & 2 and Genomics, Volume 1 & 2

Phase 3: Scaling up NLP, ML, AI to LPBI Group’s FOUR Corpuses Using LPBI’s Vendor of Choice:

TNS #2: Blockchain Transactions and broadcasting to communities in the Health Care Sector – THE ONLY WAY TO MONETIZE our content by narrow casting to Health Care Communities: BustIQ – lined them up and are willing to build the Front End

TNS #3: Podcasts – will not be a Money maker – will be a Reputation Builder – very important in Pharmaceutical MEDIA

TNS #4: Conversion e-Books to Audio and Articles to SoundCloud Audio files – Text to Audio [SEE New Yorker] – HAS POTENTIAL

TNS #5: Joint venture with Dr. Nir for Drug Discovery:

TNS #6: e-Books Translations into Japanese, Spanish, Russian

These are two distinctive entities

2.0 LPBI, 1/2021 – 12/2025 – TNS #1,2,3,4,5,6, above. Executive Summary

https://pharmaceuticalintelligence.com/leaders-in-pharmaceutical-business-intelligence/

1.0 LPBI, 4/2012 – 12/2020 – Executive Summary

https://pharmaceuticalintelligence.com/home-website-front-page/

Cumulative Revenue Potential PREDICTION of Journal Articles: Under Two Growth Assumption Regimes and Two Prediction Models

RED & BLUE Lines

A. Rate of Articles published in 2021-2025 is trending 2017, 2018, 2019, 2020

RED Line – A Marked Point Process Model: $48MM for Journal Valuation

BLUE Line – A Conservative Assumption-based Growth Prediction (Joel)

BROWN & GREEN Lines

B. No New Articles after 12/2020 will be published

BROWN Line – A Marked Point Process Model – Assuming Last article published on 12/31/2020

GREEN Line – A Conservative Assumption-based Growth Prediction (Joel) – Assuming Last article published on 12/31/2020

Data Source:

WordPress.com Web Statistics of 1.8 Million Views of 6,000 Scientific Articles, 6/30/2020

[for the Annual 2020 data: the first 6 months x2].

4/2012 – 12/2020 – ACTUALS

2021 – 2025 – FORECAST

Our 1.0 LPBI portfolio of Intellectual Property (IP) include TEN asset classes

UPDATED on 8/20/2021

To these TEN IP Asset Classes – add THREE IP Asset Classes by 2.0 LPBI

2.0 LPBI is a Very Unique Organization

2.0 LPBI all Products of NLP, see Yields for Mission #1, above

PLUS Pipeline Products, 2021-2025 beyond 1.0 Ten IP Asset Classes: XI, XII, XIII

IP Asset Class XI (Queries yielding results on the Fly) – ending up in Blockchain storage available for monetization as a new product

New Digital Products as a result of Discovery 💡 of new digital products derived from and created for the new queries by users to be generated on the fly not in existence in the knowledge graph database

In addition, all new Digital Products of Mission #3 and Mission #4

IP Asset Class XII (Mission #3) – ending up in Blockchain storage available for monetization transactions as new products

All digital products of Mission #3, below: New Genre of Scientific Books N =18, see book architecture, below,

IP Asset Class XIII (Mission #4) – ending up in Blockchain storage available for monetization transactions as new products

All digital products of Mission #4, below: New therapeutics molecules generated for 12 Galectins by Synthetic Biology software

LPBI portfolio of Intellectual Property (IP) include TEN asset classes

Asset Classes	Type	Quantity
Asset Class I	The Journal	6,067 articles on 7/9/2021

		Valuation [$XXMM] See Excel

	7/9/2021 Views 2,007,056

Asset Class II	BioMed e-Series	18 volumes



	https://pharmaceuticalintelligence.com/2019-vista/global-market-penetration-forecast-for-each-volume-in-the-16-volume-biomed-e-series/	Valuation [$5M] done by Joel & Aviva
		July 2021 128,000 page downloads in total on 7/2021. This number represents the equivalent of 64 books to have been sold [KENP to Book]

Asset Class III	eProceedings	100 events



	https://pharmaceuticalintelligence.com/2019-vista/e-proceedings-and-tweet-collections-per-conference-2013-2020-viewsdownloads-x-100-real-time-coverage-of-60-events-by-ala-sjw/	Valuation [$1.4M] done by Dr. Williams & Aviva [does not include Tweet Collection N = 40 needs Updated from 2019-2021

Asset Class IV	Platform, composition of methods and workflows for the content creation of scientific curations. See Platform:	$6MM



	Coronavirus PORTAL covers 8 topics launched on 3/14/2020

	https://pharmaceuticalintelligence.com/coronavirus-portal/

	ArtificiaI Intelligence in Genomics & Cancer Portal for Text Analysis of Journal articles and Books in these two domains by NLP, ML and AI algorithms

	https://pharmaceuticalintelligence.com/ai-in-genomics-cancer/

	2020 Summer Internship Portal

	https://pharmaceuticalintelligence.com/2020-summer-internship/

	Knowledge PORTALS System (KPS) @LPBI

	https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/

	2021 Medical Text Analysis (NLP)

	https://pharmaceuticalintelligence.com/2021-medical-text-analysis-nlp/

Asset Class V	Gallery of Biological Images in use in Articles and Books	6,000 Biological images in the Journal’s Media Gallery





Asset Class VI	Team of Experts	BIOs Final Improvement Team (FIT) aka LPBI US and LPBI India



	See Portal Platform:	$3MM

	• Knowledge Platform System (KPS)

	https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/	New Organizational Chart [w-i-p]

Asset Class VII	Royalties on BioMed e-Series:Page downloads, Book borrowings and Book sale	July 2021 145,000 page downloads in total on 7/21/2021. This number represents the equivalent of 70 books to have been sold [KENP to Book]





Asset Class VIII	Subscribers to the Website	2,641 on 7/9/2021



Asset Class IX	INTANGIBLE ASSETS & Intrinsic Value = Good Will	TBD



Asset Class X	e-VOICES PODCASTING Audio Library	A Podcast is shared FREE as industry standard, Entire Podcast Libraries commend a price





	e-VOICES Podcasting, 2019 – 2021 Podcasts on LPBI Leaders. 7/2021 a Library of Podcasts is developed for “Interviews with Scientific Leaders” N = +280 podcasts

We estimate revenue potential of each entity to be

~~ $XX Million for 1.0 LPBI [Above Ten IP Asset Classes]

Graph above present the Valuation of IP Asset Class I

~~ $XX Million for 2.0 LPBI [Excel Sheet for Financial Projection was developed in 8/2020]

~~ $ XXX Million for 1.0 LPBI plus 2.0 LPBI

The feedback that we will get from the Investment Banker will guide the TIMING and the Strategy

ALL ACTIVE Member of the Final Improvement Team (FIT) on record for the EXIT will be in constant communication regarding all of the above
Personal PORTAL for each member of FIT is displayed on https://pharmaceuticalintelligence.com/knowledge-portals-system-kps/
Meg Baker is considering a collaboration in the JOINT VENTURE (LPBI X%) and Dr. Raphael Nir (7X%) on Galectins & Synthetic Biology in Drug Discovery
Our Podcast Library is growing – See Table, below

Development Plan for e-VOICES Podcasting, 2019 – 2021*

https://pharmaceuticalintelligence.com/audio-podcasts/

Podcast Interviewer	INTERVIEWEE(S)	Subject	Date	Audio/Video/ Narrator

TBD	Dr. Stephen J. Williams, Dr. Irina Robu & Dr. Aviva Lev-Ari	3D BioPrinting in Medicine	5/2019	Audio
Gail S. Thornton	Prof. Feldman	Evolution Biology and Population Genetics	3/17/2020	Audio
Gail S. Thornton	Dr. Larry H. Bernstein, MD, FCAP	Life Memoirs in Clinical Pathology Told	10/12/2020	Audio Narrator: Dr. S.J. Williams
Gail S. Thornton	Dr. Sudipta Saha	Research in Reproductive Technology	11/7/2020	Audio

TBD	Dr. Justin D. Pearlman, MD, PhD	Cardiac Imaging – Evolution of Diagnostic Methods	4Q 2020	Audio
TBD	Dr. Raphael Nir	From Big Pharma to Biotech Entrepreneurship	2021	Audio
TBD	Dr. Meg Baker	GlycoBiology in Practice	2021	Audio
TBD	Dr. Ofer Markman	Memories of Procognia	2021	Audio
TBD	Dr. Irina Robu	AI & Tissue Engineering	2021	Audio
TBD	Dr. Williams	Preferably 3^rd party interviewer sourced by Gail. Topic: AI & Genomics	2021	Audio
TBD	Dr. Aviva Lev-Ari	Preferably 3^rd party interviewer sourced by Gail. Topic: Curation & ML	2021	Audio

Schedule for 2021 Newsletters posted https://pharmaceuticalintelligence.com/newsletter/

DETAILS about IP Asset Class I: LPBI Journal, IP Asset Class II: BioMed e-Series and IP Asset Class III: Biotech & Medical Conference e-Proceedings and Tweet Collections

Our VAST intellectual property (IP) portfolio includes three asset classes:

IP Asset Class I: LPBI Journal

https://lnkd.in/eEw5q7N

+1.8Million eReaders, +5900 scientific articles, +700 categories of research

IP Asset Class II: BioMed e-Series

https://lnkd.in/ekWGNqA

16 Volumes in Medicine

What make our e-Books UNIQUE: An Example

Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology. Published on 12/28/2019

No other book covers the same topics in a single volume. In terms of synergy, this book combines:
1. Content curation in article format with embedded videos and audio podcasts
2. Conference e-Proceedings based on real-time coverage by the authors and editors of this book.
3. Archived tweets of quotes from speakers at leading Biotech conferences, posted in real-time by the same authors

It integrates in a single volume four distinct perspectives: (a) basic science, (b) technologies & methodologies, (c) clinical aspects, and (d) business and legal aspects.

The material in this book represents the scientific frontier in Biological Sciences and Medicine related to the Genomics aspects of Disease Onset. It addresses:
1. All aspects of life: the Cell, the Organ, the Human Body and Human Populations
2. All methodologies of genomic data analysis: Next Generation Sequencing, Gene Editing, AI, Single Cell Genomics, Evolution Biology Genomics, Simulation Modeling in Genomics, Genotypes and Phenotypes Modeling, measurement of Epigenomics effects on disease, and developments in Pharmaco-Genomics

Artificial Intelligence in Medicine is covered in Part 3 of the e-Book. 3.1 to 3.5 represent the frontier in this emerging field:

3.1 The Science

3.2 Technologies and Methodologies

3.3 Clinical Aspects

3.4 Business and Legal

3.5 Latest in Machine Learning (ML) Algorithms harnessed for Medical Diagnosis: Pattern Recognition & Prediction of Disease Onset

No other book incorporates 74 e-Proceedings created in real time by the Book’s authors and editors

No other book incorporates four collections of Tweets representing quotes from speakers at global leading conferences on Genomics

No other book has 13 locations of Videos and Audio Podcasts that serve to enrich the e-Reader’s experience

No other book has 326 articles on the topics included in the Book’s title: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology

IP Asset Class III: Biotech & Medical Conference e-Proceedings

https://lnkd.in/dc2qGAK

Corpus of 70 events covered in real time yielding 60 e-Proceedings and 36 Tweet Collections

OTHER ASSET CLASSES: IV, V, VI, VII, X

Asset Class IV is the platform, composition of methods and workflows for the content creation of scientific curations
Asset Class V is a Gallery of 5,100 images used in the articles and books
Asset Class VI is the Team of Experts
Asset Class VII are the Royalties on BioMed e-Series:

e-Book age down loads,
e-Book borrowings and
e-Book sale

Asset Class X are the e-Voices Podcasting – Audio Podcasts Library https://pharmaceuticalintelligence.com/audio-podcasts/

Asset List showing Value:

@@@@@ TANGIBLE ASSETS:

1. The Journal has 1,829,736 eReaders on 9/25/2020 – ASSET CLASS I

— It has +5900 articles

— It demonstrates > 7500 comments by Scientists for +5900 articles

— It has +10K tags counted by the computer

— It has +700 categories of research in SIX disciplines among them the most complex are

Cell signaling
ATP
Autophage
Computational Biology and NGS
Cardiac imaging
Endosome
Liposomes

— It has 2,549 subscribers on 8/18/2020

2. The BioMed e-Series – ASSET CLASS II

Royalties structure:

– 121,547 page downloads in total on 8/31/2020

– x book borrowing

– y book sale – suppressed by Unlimited Prima Membership: READ FOR FREE and Pay per view

– 65% of book sales revenues is retained by Amazon

3. e-Proceedings and Activity on Twitter.com – ASSET CLASS III

LPBI is the One and only e-Proceedings generator at end of Conference by one-Click

The #WMIF19 Influencers via @symplur‘s #Healthcare Hashtags http://bit.ly/WMIF19– By Mentions and By Tweets Ranked #4: @pharma_BI and Ranked #2: @AVIVA1950, respectively. Ranked #3 via @NodeXL Betweenness Centrality http://bit.ly/2KB6cPN

For @AVIVA1950, Founder, LPBI Group @pharma_BI: Twitter Analytics [Engagement Rate, Link Clicks, Retweets, Likes, Replies] & Tweet Highlights [Tweets, Impressions, Profile Visits, Mentions, New Followers]

https://analytics.twitter.com/user/AVIVA1950/tweets

@@@@@ INTANGIBLE ASSETS equal e-Reputations

A. Institutions following @AVIVA1950 and @pharma_BI include the marque organizations as follows:

TECHNION
WEIZMANN INSTITUTE
HEBREW UNIV
PARTNERS INNOVATIONS: MGH & BWH
BROAD INSTITUTE @MIT & @Harvard
Bayer US
PhRMA
Keck Medicine of USC
Intermountain Cancer
MassBio
Hadasit Bio Holdings
BioWorld
Bell Labs
BCM_CVRI
MIT Spectrum
TED Talks

B. LPBI’s Founder is followed by 500 CEOs 200 CEOs in Biotech & Pharma on LinkedIn and

C. LPBI’s Founder has ~7300 followers 1st level connection on LinkedIn.

Distribution of 1st level LinkedIn connection by Industry

Chemicals	2366
Pharmaceuticals	919
Biotechnology	841
Oil & Energy	664
Staffing and Recruiting	218
Management Consulting	218
Research	207
Information Technology and Services	198
Environmental Services	183
Plastics	171
Food & Beverages	137
Marketing and Advertising	115
Human Resources	96
Food Production	93
Financial Services	92

D. LPBI’s Founder is bestowed by >1000 endorsements

@@@@ LPBI Group’s Social Media Presence in 2020

Our Social Media Presence in 2020 is by two handles on Twitter.com

@pharma_BI

Official handle of my Venture: Leaders in Pharmaceutical Business Intelligence (LPBI) Group,

Boston, MA, NJ, CA, PA, ME, DE, India, Israel & Canada

Institutional versus Personal: Statistical Analysis of Two Twitter Handles – @pharma_BI (LPBI Group’s Official) and @AVIVA1950 (LPBI Group’s Founder’s Personal) – Comparative Analysis of Followers and The Followers of these two Handles’ Followers

LPBI Group is mostly HONORED to be followed by [from an Excerpt of 136 Followers of the Twitter Account @pharma_BI from the List of 505 Followers] by the Number of their Followers on 3/20/2019

MEDIA organizations as Followers of @pharma_BI the Official Twitter Account of LPBI Group (136 out of 505 Followers): Number of Followers’ Followers, Institutions (I) and Individuals (Persons(P)), RED = Mostly Honored to be followed by

Excerpt of 136 Followers of @pharma_BI (from the List of 505 Followers) by the Number of their Followers on 3/20/2019

@AVIVA1950

Personal account of Aviva Lev-Ari, PhD, RN – LPBI Group’s Founder

2019 World Medical Innovation Forum on AI in Medicine – Aviva’s rankings as Influencer

The #WMIF19 Influencers via @symplur‘s #HealthcareHashtags http://bit.ly/WMIF19– By Mentions and By Tweets Ranked #4: @pharma_BI and #2: @AVIVA1950, respectively. Ranked #3 via NodeXL Betweenness Centrality http://bit.ly/2KB6cPN

https://pharmaceuticalintelligence.com/2019/04/13/the-wmif19-influencers-via-symplurs-healthcare-hashtags-http-bit-ly-wmif19-by-mentions-and-by-tweets-ranked-4-pharma_bi-and-2-aviva1950-respectively-ranked-3-via-node/